101 related articles for article (PubMed ID: 23641727)
1. Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.
Perera V; Gross AS; Polasek TM; Qin Y; Rao G; Forrest A; Xu J; McLachlan AJ
Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1115-37. PubMed ID: 23641727
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.
Laika B; Leucht S; Heres S; Schneider H; Steimer W
Pharmacogenomics J; 2010 Feb; 10(1):20-9. PubMed ID: 19636338
[TBL] [Abstract][Full Text] [Related]
3. CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.
Czerwensky F; Leucht S; Steimer W
Ther Drug Monit; 2015 Apr; 37(2):152-60. PubMed ID: 25090458
[TBL] [Abstract][Full Text] [Related]
4. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).
Nozawa M; Ohnuma T; Matsubara Y; Sakai Y; Hatano T; Hanzawa R; Shibata N; Arai H
Ther Drug Monit; 2008 Feb; 30(1):35-40. PubMed ID: 18223460
[TBL] [Abstract][Full Text] [Related]
5. Variables associated with high olanzapine dosing in a state hospital.
Botts S; Littrell R; de Leon J
J Clin Psychiatry; 2004 Aug; 65(8):1138-43. PubMed ID: 15323601
[TBL] [Abstract][Full Text] [Related]
6. CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients.
Fekete F; Menus Á; Tóth K; Kiss ÁF; Minus A; Sirok D; Belič A; Póti Á; Csukly G; Monostory K
Sci Rep; 2023 Oct; 13(1):18507. PubMed ID: 37898643
[TBL] [Abstract][Full Text] [Related]
7. Cigarette smoking and heavy coffee consumption affecting response to olanzapine: The role of genetic polymorphism.
Djordjevic N; Radmanovic B; Cukic J; Baskic D; Djukic-Dejanovic S; Milovanovic D; Aklillu E
World J Biol Psychiatry; 2020 Jan; 21(1):29-52. PubMed ID: 30513034
[No Abstract] [Full Text] [Related]
8. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers.
Shirley KL; Hon YY; Penzak SR; Lam YW; Spratlin V; Jann MW
Neuropsychopharmacology; 2003 May; 28(5):961-6. PubMed ID: 12644842
[TBL] [Abstract][Full Text] [Related]
9. Impact of CYP1A2 genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis.
Na Takuathung M; Hanprasertpong N; Teekachunhatean S; Koonrungsesomboon N
Acta Psychiatr Scand; 2019 Jan; 139(1):15-25. PubMed ID: 30112761
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of olanzapine metabolism.
Söderberg MM; Dahl ML
Pharmacogenomics; 2013 Aug; 14(11):1319-36. PubMed ID: 23930678
[TBL] [Abstract][Full Text] [Related]
11. Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients.
Ghotbi R; Mannheimer B; Aklillu E; Suda A; Bertilsson L; Eliasson E; Osby U
Eur J Clin Pharmacol; 2010 May; 66(5):465-74. PubMed ID: 20143052
[TBL] [Abstract][Full Text] [Related]
12. Safety of olanzapine use in adolescents.
Schulz C; Haight RJ
Expert Opin Drug Saf; 2013 Sep; 12(5):777-82. PubMed ID: 23876012
[TBL] [Abstract][Full Text] [Related]
13. The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine.
Hattori S; Suda A; Miyauchi M; Shiraishi Y; Saeki T; Fukushima T; Fujibayashi M; Tsujita N; Ishii C; Ishii N; Moritani T; Saigusa Y; Kishida I
BMC Psychiatry; 2020 Feb; 20(1):72. PubMed ID: 32070304
[TBL] [Abstract][Full Text] [Related]
14. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
15. The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia.
Lin YC; Ellingrod VL; Bishop JR; Miller DD
Ther Drug Monit; 2006 Oct; 28(5):668-72. PubMed ID: 17038883
[TBL] [Abstract][Full Text] [Related]
16. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
17. Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents.
Ren XS; Qian S; Lee AF; Herz L; Miller DR; Kazis LE
J Clin Pharm Ther; 2006 Feb; 31(1):57-65. PubMed ID: 16476121
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia.
Takeuchi H; Fervaha G; Lee J; Agid O; Remington G
Eur Neuropsychopharmacol; 2015 Mar; 25(3):295-302. PubMed ID: 25649680
[TBL] [Abstract][Full Text] [Related]
20. Association of the genetic polymorphisms of metabolizing enzymes, transporters, target receptors and their interactions with treatment response to olanzapine in chinese han schizophrenia patients.
Yan P; Song M; Gao B; Wang S; Wang S; Li J; Fang H; Wang C; Shi J
Psychiatry Res; 2020 Nov; 293():113470. PubMed ID: 32992097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
